AbCellera Biologics Inc
ABCL
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.12B
Close$
$-4.46
140.7% downside
Current Fair Value
140.7% downsideOvervalued by 140.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.12 Billion |
|---|---|
| Enterprise Value | $2.15 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.49 |
| Beta | 1.15 |
| Outstanding Shares | 305,557,294 |
Return
| Return on Equity | -18.38% |
|---|---|
| Return on Assets | -12.59% |
| Return on Invested Capital | -16.32% |
Valuation & Multiples
| P/E Ratio | -12.83 |
|---|---|
| PEG | -21.53 |
| Price to Sales | - |
| Price to Book Ratio | 5.49 |
| Enterprise Value to Revenue | 32.53 |
| Enterprise Value to EBIT | -10.51 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.17 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.17
Average shareholder expectationRevenue Estimate
$7.85 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.18
Average shareholder expectationRevenue Estimate
$5.32 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 2.0981▲ 153.76% |
|---|---|
| Total Calls | 1,652,400▲ 44.11% |
| Total Puts | 3,466,900▲ 439.43% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 41.01%▲ 4.71% |
|---|---|
| Total Invested | $433.98M▲ 17.10% |
| Investors Holding | 152▼ 3.00% |
ESG Score
No data